1 / 56

The REACH Registry

kaydence
Download Presentation

The REACH Registry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. The REACH Registry An International, Prospective Observational Study in Subjects at Risk of Atherothrombotic Events in an Outpatient Setting

    2. Background

    3. Burden of Disease

    4. Atherothrombosis – a Generalized and Progressive Disease Process1,2

    5. Major Role of Platelets in Atherothrombosis1

    6. Major Manifestations of Atherothrombosis1

    7. Cardiovascular Disease is the Leading Cause of Death Worldwide1

    8. Atherothrombosis Significantly Shortens Life Expectancy1

    9. Risk of Atherothrombosis

    10. Atherothrombosis is Often Found in More Than One Arterial Bed*1

    11. Patients with Previous Atherothrombotic Events are at Increased Risk of Further Events

    12. Risk Factors can Create High Risk of MI and Stroke, Even With No History of These Events1

    13. Risk of CHD Increased in Patients with Multiple Risk Factors1

    14. Many Risk Factors are Easily Identified1,2

    15. REACH Registry: Background

    16. REACH Registry: Rationale and Objectives

    17. REACH Registry: a Global Observational Study of around 68,000 Patients in 44 Countries Who Are at High Risk of Atherothrombosis1 Rationale Evaluation of atherothrombosis is still limited because previous surveys have: Focused on studying specific risk factors, or ‘single’ manifestations of the disease (e.g. heart disease) Focused mostly on hospitalized or hospital-treated patients with stringent inclusion criteria Been conducted in either North America or Europe

    18. REACH Registry: a Global Observational Study of around 68,000 Patients in 44 Countries Who Are at High Risk of Atherothrombosis1 The REACH Registry should have these added advantages: The most globally inclusive and geographically extensive registry of patients at high risk of heart attack and stroke Includes a broad spectrum of patient types – with or without a previous history of disease Provides data from a ‘real world’ setting, reflecting daily practice

    19. REACH Registry: Objectives1

    20. Improving the Management of Cardiovascular Disease Risk

    21. What do we hope the REACH Registry will achieve?

    22. REACH Registry: Design

    23. REACH Registry Timeline

    24. REACH Registry Inclusion Criteria1

    25. REACH Registry Exclusion Criteria1

    26. Physician Selection: Reflection of Each Country’s Management of Cardiovascular Risk1

    27. Patient Selection: Patients Fitting Inclusion Criteria1

    28. REACH Registry: Baseline Results Data shown may differ slightly from published abstracts owing to a subsequent database lock

    29. Aims of the Baseline Analysis1 Aim: To determine whether atherosclerosis risk factor prevalence and treatment would demonstrate comparable patterns in many countries around the world Conclusion: Classic cardiovascular risk factors are consistent and common, but are largely undertreated and undercontrolled in many regions of the world

    30. REACH Registry: Conclusions From Baseline Cardiovascular risk profiles are common and consistent across different geographic locations and patient types:1 Treatment goals are consistently not achieved in all patient types worldwide Established therapies are consistently underused in high-risk populations Women are undertreated despite commonly having more severe disease2 The REACH Registry patients with PAD have:3 A high prevalence of concomitant disease in other vascular beds Multiple risk factors for atherothrombosis, including pre-diabetes and undiagnosed diabetes Underutilization of appropriate medications to treat cardiovascular risk The REACH Registry patients with cerebrovascular disease have:4 A high prevalence of multiple risk factors for atherothrombosis and disease in other vascular beds Underutilization of appropriate medications

    31. A Large and Far-Reaching International Survey of Atherothrombosis*1

    32. Broad Geographic Representation*1

    33. Age and Gender of the Symptomatic Baseline Population*1

    34. Classic Cardiovascular Risk Factors are Consistent and Common within the Symptomatic REACH Registry Baseline Population*1

    35. Age and Gender of the Multiple Risk Factor Population at Baseline*1

    36. Classic Cardiovascular Risk factors are Consistent and Common within the Multiple Risk Factor REACH Registry Baseline Population*1

    37. Primary Care Practitioners (GPs and internists) Formed the Majority of REACH Registry investigators

    38. High Prevalence of Polyvascular Disease (Disease in More Than One Arterial Bed)

    39. ~ 1/4 of Patients with CAD Have Polyvascular Disease1

    40. ~ 2/5 of Patients with Cerebrovascular Disease Have Polyvascular Disease1

    41. ~ 3/5 of Patients with Symptomatic PAD Have Polyvascular Disease1

    42. A Large Minority had Polyvascular Disease in the REACH Registry*1

    43. Undertreatment of Patients with Atherothrombosis Worldwide

    44. Undertreatment of Risk Factors in Patients Worldwide*1

    45. Established Therapies are Consistently Underused in All Patient Types*1

    46. High Prevalence of Overweight and Obesity in Most Regions*1

    47. Overweight and Obesity Highly Prevalent in Multiple Risk Factor Patients in Most Regions*1

    48. High Prevalence of Concomitant Risk Factors in Patients with Symptomatic PAD*1

    49. PAD Patients are Less Likely than Other Patients to Use Established Therapies*1

    50. Risk factors are consistently found across all disease sub-populations*1

    51. REACH Registry: Today and Beyond

    52. Participating Organizations and Scientific Committees

    53. Scientific Committee1

    54. Publication Committee1

    55. Participating Organizations The REACH Registry is sponsored jointly by

    56. REACH Registry: Further Information

More Related